RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)
RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)
RevolKa Fueling Up AI Protein Engineering Platform-based Therapeutic Program
SENDAI Japan- Jun 30th, 2025. RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein® has announced its participation in a research and development program funded by a government grant of 54 million JPY (approximately US$372K for the first year) from the Japanese Agency for Medical Research and Development (AMED). This project, set to continue over 4 years, is led by Prof. Mitsuo Umetsu of Tohoku university, who also serves as RevolKa’s Chief Scientific Officer. This opportunity will further accelerate RevolKa’s rare disease drug discovery and development efforts, previously announced on July 30th, 2024. (https://www.revolka.com/news/english/collab-en/a65).
RevolKa’s core technology, aiProtein®: a robust directed protein evolution platform integrated with AI (artificial intelligence) creates exceptionally high performance proteins, going beyond natural evolution and offering advantages for therapeutic strategies. aiProtein® has generated many successful outcomes with many partner companies.
About aiProtein® Technology
RevolKa’s proprietary technology, aiProtein® is an AI-assisted directed evolution platform for proteins. Naturally occurring proteins are linear polymers composed of amino acids and their derivatives, folding into a tertiary structure through internal complex atomic interactions to exhibit biological functions. Proteins have evolved their biological functional complexity over hundreds of millions of years. However, the relationship between protein sequence, structure, and function remains poorly understood to enable rational design of protein sequences for specific function. RevolKa’s AI engine is trained with sequence-function relationship data, enabling statistical prediction of optimized protein sequences with desired functions. Furthermore, aiProtein® can evolve multiple properties simultaneously. This technology is a powerful and cost-effective solution for creating novel and highly functional proteins suitable for pharmaceutical and industrial applications.
About RevolKa Ltd.
RevolKa is a venture-backed biotechnology company founded in April 2021 by academic and industry experts in biotechnology and artificial intelligence. Our mission is to contribute to human well-being by creating novel proteins for therapeutics and industrial applications using our proprietary technology, aiProtein®. The name "RevolKa" is derived from the Latin word for evolution, "evolutio” and the Ainu (an indigenous Japanese people) word for raise, “reska”. RevolKa’s headquarters and laboratories are located in Sendai, Japan. The company’s investors include D3 LLC, Tohoku University Venture Partners Co., Ltd., DEEPCORE Inc., and SBI Investment Co., Ltd. For more information, visit https://www.revolka.com/en/.
250630_Release_RevolKa Joins Research and Development Program for Innovative Biologics Funded by the AMED.pdf